Massachusetts Financial Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Massachusetts Financial Services’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,396	Closed	-$159K	–	889
2023 Q4	$159K	Sell	30,396 -960	-3%	-$9.48K	﹤0.01%	831
2023 Q3	$494K	Sell	31,356 -1,203	-4%	-$21.6K	﹤0.01%	806
2023 Q2	$633K	Sell	32,559 -767	-2%	-$18.2K	﹤0.01%	779
2023 Q1	$945K	Buy	33,326 +14,005	+72%	+$416K	﹤0.01%	768
2022 Q4	$565K	Buy	19,321 +407	+2%	+$12.9K	﹤0.01%	814
2022 Q3	$500K	Buy	18,914 +5,065	+37%	+$186K	﹤0.01%	816
2022 Q2	$615K	Buy	+13,849	New	+$636K	﹤0.01%	800

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Massachusetts Financial Services's EGRX Position: Q1 2024 in Review

Massachusetts Financial Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 30,396 shares — an estimated $159K sold.

Massachusetts Financial Services first reported a position in EGRX in Q2 2022 and held it in 7 quarters. The position peaked at $945K in Q1 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Massachusetts Financial Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Massachusetts Financial Services sold 30,396 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $159K.
Massachusetts Financial Services first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2022 and held it in 7 quarters.
Massachusetts Financial Services's Eagle Pharmaceuticals, Inc. position peaked at $945K in Q1 2023.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Massachusetts Financial Services's 13F filing for Q1 2024, filed 14 May 2024.